IP: Dr. Jesús Sánchez Yagüe

Resumen del proyecto: Endoscopic retrograde cholangiopancreatography (ERCP) is sometimes associated with post- ERCP acute pancreatitis (AP). It would be very useful the finding of molecular biomarkers that allowed the identification of patients that will developed post-ERCP pancreatitis. The goals of the present project are to perform in vivo studies (in two experimental models of AP: cerulein -Cer- and taurocholate) of: (1) the changes in protein and phosphoprotein targets during the early phase of AP and, once the disease has been fully developed, after the blocking/modulation (by using specific inhibitors) of MAPKs, cAMP as well as after the inhibition of cellular infiltration through the use of proteomic TMT and 2-DE techniques of pancreatic fractions; (2) the modulation of the expression at gene level (RT-PCR) of the protein targets unmasked in goal number 1; (3) changes in the hidroelectrolyte ductal secretion (in fragmens of biliopancreatic ducts by using digital videomicroscopy), as well as in the levels of P substance, CGRP and TNF-a (in plasma by ELISA), in both experimental models of AP without or after blocking/modulation of cAMP and/or infiltration. Also, the analysis in human plasma from patients with post-ERCP AP in a view to find out clinical biomarkers of: (4) the proteins that based on our previous studies, are known to change in the pancreas of the rat during the early phase of AP (Western blotting); (5) the changes in protein and phosphoprotein targets (proteomic TMT and 2-DE techniques), along the development of post-ERCP AP; (6) the levels of P substance, CGRP and TNF-a (ELISA).

Entidad financiadora: Instituto de Salud Carlos III